MULTIPLE MYELOMA REFRACTORY
Clinical trials for MULTIPLE MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Target cell therapy tested for tough blood cancer
Disease control Not yet recruitingThis early-stage study is testing a new type of CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to other treatments. The therapy involves modifying a patient's own immune cells to attack the cancer by targeting two specific markers on …
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Apr 02, 2026 00:26 UTC
-
New drug aims to boost Cancer-Fighting CAR-T cells in tough myeloma cases
Disease control Not yet recruitingThis early-stage study is testing whether adding an experimental drug called NT-I7 to standard CAR-T cell therapy helps control multiple myeloma for longer. The research will involve 40 adults with myeloma that has returned or stopped responding to other treatments. Participants …
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage trial is testing a new personalized cell therapy called S103 for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them to target the cancer, and infuse them bac…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Turmeric in a shot? early test for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis is a very early study to find the safest dose of a new IV drug made from curcumin, the active part of turmeric. It will involve 20 adults with advanced multiple myeloma that has returned or stopped responding to all standard treatments. The main goal is to see what side effe…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Faster Cancer-Fighting cells tested in groundbreaking trial
Disease control Not yet recruitingThis is a first-in-human study to test the safety of a new, experimental CAR-T cell therapy called UF-KURE-BCMA for patients with multiple myeloma that has returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to t…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC